Immunic, Inc. (NASDAQ:IMUX - Get Free Report) saw a significant drop in short interest during the month of February. As of February 15th, there was short interest totalling 2,550,000 shares, a drop of 32.0% from the January 31st total of 3,750,000 shares. Based on an average daily volume of 933,800 shares, the days-to-cover ratio is presently 2.7 days.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the company. Invesco Ltd. acquired a new stake in Immunic during the fourth quarter worth $37,000. Virtu Financial LLC acquired a new stake in shares of Immunic during the 3rd quarter valued at about $50,000. HB Wealth Management LLC bought a new stake in Immunic in the fourth quarter valued at about $81,000. Barclays PLC bought a new stake in Immunic in the fourth quarter valued at about $84,000. Finally, Jane Street Group LLC raised its position in Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock worth $116,000 after purchasing an additional 38,553 shares in the last quarter. 51.82% of the stock is currently owned by institutional investors and hedge funds.
Immunic Stock Down 1.7 %
Immunic stock traded down $0.02 during trading hours on Thursday, hitting $1.15. The stock had a trading volume of 566,093 shares, compared to its average volume of 974,743. Immunic has a fifty-two week low of $0.92 and a fifty-two week high of $2.11. The company has a market cap of $103.59 million, a PE ratio of -0.93 and a beta of 1.89. The company has a 50-day moving average of $1.04 and a two-hundred day moving average of $1.25.
Analyst Ratings Changes
A number of equities analysts have recently commented on IMUX shares. D. Boral Capital reiterated a "buy" rating and issued a $17.00 price objective on shares of Immunic in a research note on Wednesday, February 26th. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of Immunic in a research report on Friday, February 21st. Finally, StockNews.com lowered Immunic from a "hold" rating to a "sell" rating in a report on Saturday, February 22nd. One analyst has rated the stock with a sell rating, six have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $12.67.
Check Out Our Latest Analysis on Immunic
About Immunic
(
Get Free Report)
Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Read More
Before you consider Immunic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.
While Immunic currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
